

Curriculum Vitae
Farhad Jadidi-Niaragh, PhD
Assistant Professor, Department of Immunology
Tabriz University of Medical Sciences

Date September 19, 2024

Contact Information

Business Address: Department of Immunology, Faculty of Medicine, Tabriz
University of Medical Sciences
Daneshgah Street,
Tabriz, 5166614766
Business Phone Number: +98 41 33364665
Fax: +98 41 33364665
Email: farhad_jadidi1986@yahoo.com
Foreign Languages: English, Turkish

Education

2004 - 2008 B.S., Cell and Molecular Biolog; Department of Biology, Faculty of Sciences,
Shiraz University, Shiraz, Iran.
2008 - 2012 M.S., Immunology; Department of Immunology, School of Public Health, Tehran
University of Medical Sciences, Tehran, Iran.
2012 - 2016 Ph.D., Immunology; Department of Immunology, School of Public Health,
Tehran University of Medical Sciences, Tehran, Iran.

Employment History

2016-now Assistant Professor, Faculty of Medicine, Tabriz University of Medical Sciences

Professional Society Membership

2011-2016 General Member, European Association for Cancer Research
2011- present General Member, Iranian Society for Immunology and Allergy

Honors and Awards

2017 The member of National Elites Foundation of Iran
2008 Fifth national rank in the M.Sc. entrance exam (Ministry of Health) of Medical
Immunology.
2012 First national rank in the Ph.D. entrance exam (Ministry of Health) of Medical
Immunology.

- 2014 Avicenna award for the best M.Sc. thesis in the 15th Avicenna festival.
2016 Avicenna award for the best PhD student researcher in the 2th Avicenna student festival.
2021 Selected as a top researcher of Faculty of Medicine in Tabriz University of Medical Sciences.

Clinical Activities

2018-present The immunology technical manager of the medical diagnosis laboratory of Razi Hospital, Tabriz, Iran.

Local and National Service

2022-present *Review Editor in section Microbial Immunology for Frontiers in Immunology* (<https://loop.frontiersin.org/people/83674/editorial>)

2023-present Associate Editor for International Journal of Aging (<http://www.ijage.com/EditorialBoard>)

Teaching Service

Undergraduate Student Teaching

2017-present Teaching Immunology to students of laboratory sciences, nursing, operating room bachelor, and midwifery, two semesters per year.

Medical Student Teaching

2017-present Teaching Immunology to medical students, 2nd, and 3rd year medical students - one semester per year.

Resident and Fellow Teaching

2017-present Teaching immunology to dental residents, one semester per year.

Post-Graduate Teaching

2017-present Teaching immunology to master's students in immunology, biochemistry and parasitology. Teaching immunology to immunology and tissue engineering PhD students/two semesters per year.

Laboratory Techniques

- Immunological techniques: such as ELISA, ELISPOT, LTT, MTT, XTT, TUNEL, cytokine assay, western blotting and so on.
- Immunofluorescence
- Flow cytometry
- Cell isolation techniques such as Density gradient, MACS, Nylon wool, rosette, ...
- Cell proliferation assays such as H3 thymidine incorporation, BrdU, CFSE, ...
- Conventional molecular biology techniques including: DNA and RNA extraction, PCR, Real Time PCR, gene Silencing by siRNA and shRNA, microRNA, RT-PCR Cloning, Expression
- Biochemistry techniques: PAGE, SDS-PAGE, purification techniques including affinity chromatography, Ion exchange, Gel filtration
- Animal cell culture technology including Isolation and culture of primary cells, cell line culture, Passage, Transformation, Transfection.
- Animal manipulation: Immunization, Tumor inoculation, Immunotherapy of Tumors
- Nanoimmunology related techniques, production and characterization of chitosan based nanoparticles, graphen, spion and ...

Publications

Peer-reviewed journal articles

1. Mirshafiey A, **Jadidi-Niaragh F**, Immunopharmacological role of the leukotriene receptor antagonists and inhibitors of leukotrienes generating enzymes in multiple sclerosis. *Immunopharmacology and Immunotoxicology*. 2010;32(2):219-27.
2. Mirshafiey A, **Jadidi-Niaragh F**, Prostaglandins in pathogenesis and treatment of multiple sclerosis. *Immunopharmacology and Immunotoxicology*. 2010;32(4):543-54.
3. **Jadidi-Niaragh F**, Mirshafiey A, Histamine and histamine receptors in pathogenesis and treatment of multiple sclerosis. *Neuropharmacology*. 2010 S;59(3):180-9.
4. **Jadidi-Niaragh F**, Mirshafiey A, Therapeutic approach to multiple sclerosis by novel oral drug. *Recent Patent on Inflammatory Allergy Drug Discovery*. 2011 Jan;5(1):66-80,
5. **Jadidi-Niaragh F**, Mirshafiey A, Regulatory T-cell as orchestra leader in immunosuppression process of multiple sclerosis. *Immunopharmacology and Immunotoxicology*. 2011; 33(3): 545–567
6. **Jadidi-Niaragh F**, Mirshafiey A, Th17 cell, the New Player of Neuroinflammatory Process in Multiple Sclerosis. *Scandinavian Journal of Immunology*. 2011; 74 (1): 1–13
7. **Jadidi-Niaragh F**, Mirshafiey A, The Deviated Balance between Regulatory T cell and Th17 in Autoimmunity. *Immunopharmacology and Immunotoxicology*. 2012 Oct;34(5):727-39
8. **Jadidi-Niaragh F**, Jeddi-Tehrani M, Ansaripour B, Razavi SM, Sharifian RA, Shokri F, Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia. *Medical Oncology*. 2012 Dec;29(5):3561-9
9. **Jadidi-Niaragh F**, Shegarfi H, Naddafi F, Mirshafiey A. The Role of Natural Killer Cells in Alzheimer's Disease. *Scandinavian Journal of Immunology*. 2012 Nov;76(5):451-6.

10. Gol-Ara M, **Jadidi-Niaragh F**, Sadria R, Mirshafiey A. The Role of Different Subsets of Regulatory T Cells in Immunopathogenesis of Rheumatoid Arthritis. *Arthritis*. 2012;2012:805875. doi: 10.1155/2012/805875
11. **Jadidi-Niaragh F**, Yousefi M, Hojjat-Farsangi M, Khoshnoodi J, Razavi SM, Jeddi-Tehrani M, Shokri F, Increased Frequency of CD8⁺ and CD4⁺ Regulatory T cells in Chronic Lymphocytic Leukemia: Association with Disease Progression. *Cancer Investigation*, 2013 Feb;31(2):121-31
12. **Jadidi-Niaragh F**, Ghalamfarsa G, Memarian A, Asgarian-Omran H, Razavi SM, Sarrafnejad A, Shokri F, Downregulation of IL17 producing T cells is Associated with Regulatory T Cells Expansion and Disease Progression in Chronic Lymphocytic Leukaemia. *Tumor Biology*. 2013; 34:929–940
13. Ghalamfarsa G, Hadinia A, Yousefi M, **Jadidi-Niaragh F***. The role of natural killer T cells in B cell malignancies. *Tumor Biology*, 2013; 34:1349–1360
14. Ghalamfarsa G, **Jadidi-Niaragh F**, Hojjat-Farsangi M, Asgarian-Omran A, Yousefi M, Tahmasebi F, Khoshnoodi J, Razavi SM, Saboor-Yaraghi AK, Rabbani H, Jeddi-Tehrani M, Shokri F. Differential regulation of B-cell proliferation by IL21 in different subsets of chronic lymphocytic leukemia. *Cytokine*; 62 (2013) 439–445
15. **Jadidi-Niaragh F**, Ghalamfarsa G, Yousefi M, Tabrizi MH, Shokri F, Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions. *Tumor Biology*. 2013; 34:2031–2039.
16. Azizi G, **Jadidi-Niaragh F**, Mirshafiey A. Th17 Cells in Immunopathogenesis and treatment of rheumatoid arthritis. *International Journal of Rheumatic Disease*. 2013 Jun;16(3):243-53.
17. Mirshafiey A, Asghari B, Ghalamfarsa G, **Jadidi-Niaragh F**, Azizi G. The Significance of Matrix Metalloproteinases in the Immunopathogenesis and Treatment of Multiple Sclerosis. *Sultan Qaboos University of Medical Journal*. 2014 Feb;14(1):e13-e25.
18. Yousefi B, **Jadidi-Niaragh F**, Azizi G, Hajighasemi F, Mirshafiey A. The role of leukotrienes in immunopathogenesis of rheumatoid arthritis. *Modern Rheumatology*. 2014 Mar;24(2):225-35.
19. Ghalamfarsa G, **Jadidi-Niaragh F**, Amiri MM, Razavi SM, Saboor-Yaraghi AA, Shokri F. All-trans-retinoic acid differentially regulates proliferation of normal and leukemic B cells from different subsets of chronic lymphocytic leukemia. *Nutrition and cancer*. 2015 May;67(2):1-7.
20. Gharibi T, Ahmadi M, Seyfizadeh N, **Jadidi-Niaragh F***, and Yousefi M. Immunomodulatory Characteristics of Mesenchymal Stem Cells and their role in the Treatment of Multiple Sclerosis. *Cellular Immunology* 293 (2015) 113–121.
21. Hosseini M, Haji-Fatahaliha M, **Jadidi-Niaragh F**, Majidi J, and Yousefi M. Nanoparticles as a promising therapeutic approach in cancer immunotherapy. *Artificial Cells, Nanomedicine and Biotechnology*. 2016 Jun;44(4):1051-61.
22. Kazemi T, Younesi V, **Jadidi-Niaragh F**, Yousefi M. Immunotherapeutic approaches for cancer therapy: An updated review. *Artificial Cells, Nanomedicine and Biotechnology*. 2016 May;44(3):769-79.
23. Yousefi M, Movassaghpour AA, Shamsasenjan K, Ghalamfarsa G, Sadreddini S, **Jadidi-Niaragh F***, Hojjat-Farsangi M. The skewed balance between Tregs and Th17 in chronic lymphocytic leukemia. *Future Oncology*. 2015 May;11(10):1567-82.

24. Yousefi M, Younesi V, Bayat AA, **Jadidi-Niaragh F**, Abbasi E, Razavi A, Khosravi-Eghbal R, Asgarin-Omran H, Shokri F. Comparative human and mouse antibody responses against tetanus toxin at clonal level. *Journal of Immunotoxicology*. 2016;13(2):243-8..
25. Delfan M, Ebrahim K, Baesi F, Mirakhori Z, Ghalamfarsa G, Bakhshaei P, Saboor-Yaraghi AA, Razavi A, Setayesh M, Yousefi M, **Jadidi-Niaragh F***. The immunomodulatory effects of fish-oil supplementation in elite paddlers: A pilot randomized double blind placebo-controlled trial. *Prostaglandins Leukotrienes and Essential Fatty Acids*. 2015 Aug;99:35-40.
26. Haji-Fatahaliha M, Hosseini M, Akbarian A, Sadreddini S, **Jadidi-Niaragh F**, Yousefi M. CAR-modified T-cell therapy for cancer: an updated review. *Artificial Cells, Nanomedicine and Biotechnology*. 2015 Jun 11:1-11.
27. Bahrami B, Mohammadnia-Afrouzi M, Bakhshaei P, Yazdani Y, Ghalamfarsa G, Yousefi M, Sadreddini S, **Jadidi-Niaragh F***, Hojjat-Farsangi M. Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy. *Tumor Biology*. 2015 Aug;36(8):5727-42.
28. Hosseini M, Haji Fatahaliha M, Aghebati-Maleki L, Movassagh Pour A, Rafati S, Seifi-Najmi M, Younesi V, **Jadidi-Niaragh F**, Yousefi M. Recombinant Leishmania major lipophosphoglycan 3 activates human T-lymphocytes via TLR2-independent pathway. *Journal of Immunotoxicology*. 2016;13(2):263-9.
29. Fatahaliha MH, Hosseini M, Rasolzadeh S, Bandi DS, Baradaran B, **Jadidi-Niaragh F**, Yousefi M. Analysis of human B cell response to recombinant Leishmania LPG3. *Asian Pacific Journal of Tropical Medicine*. 2015 Aug;8(8):624-9.
30. Hajivalili M, Pourgholi F, Kafil HS, **Jadidi-Niaragh F**, Yousefi M. Mesenchymal Stem Cells in the Treatment of Amyotrophic Lateral Sclerosis. *Current Stem Cell Research & Therapy*. 2016;11(1):41-50.
31. Yazdani Y, Mohammadnia-Afrouzi M, Yousefi M, Anvari E, Ghalamfarsa G, Hasannia H, Sadreddini S, **Jadidi-Niaragh F***. Myeloid-derived suppressor cells in B cell malignancies. *Tumor Biology*. 2015 Sep;36(10):7339-53.
32. Dehghanzadeh R, **Jadidi-Niaragh F**, Gharibi T, Yousefi M. MicroRNA-induced drug resistance in gastric cancer. *Biomedicine & Pharmacotherapy*. 2015 Aug;74:191-9.
33. Kokhaei P, **Jadidi-Niaragh F**, Sotoodeh Jahromi A, Osterborg A, Mellstedt H, Hojjat-Farsangi M. Ibrutinib-A double-edge sword in cancer and autoimmune disorders. *Journal of Drug Targeting*. 2015 Sep 11:1-13.
34. Namdar A, Mirzaei HR, **Jadidi-Niaragh F**, Ashourpour M, Ajami M, Hadjati J, Rezaei A. Multiple Low Doses of 5-Fluorouracil Diminishes Immunosuppression by Myeloid Derived Suppressor Cells in Murine Melanoma Model. *Iranian Journal of Immunology*. 2015 Sep;12(3):176-87.
35. Ghalamfarsa G, Mahmoudi M, Mohammadnia-Afrouzi M, Yazdani Y, Anvari E, Hadinia A, Ghanbari A, Setayesh M, Yousefi M, **Jadidi-Niaragh F***. IL-21 and IL-21 receptor in the immunopathogenesis of multiple sclerosis. *Journal of Immunotoxicology*. 2016 May;13(3):274-85.
36. Motalebnezhad M, **Jadidi-Niaragh F**, Safaie Qamsari E, Gharibi T, Bagheri S, Yousefi M. The Immunobiology of Myeloid-Derived Suppressor Cells in Cancer. *Tumor Biology*. 2016 Feb;37(2):1387-406.

37. **Jadidi-Niaragh F**, Atyabi F, Rastegari A, Mollarazi E, Kiani M, Razavi A, Yousefi M, Kheshtchin N, Hassannia H, Hadjati J, and Shokri F. Downregulation of CD73 in 4T1 Breast Cancer Cells through siRNA Loaded Chitosan-Lactate Nanoparticles. *Tumor Biology*, 2016 Jun;37(6):8403-12.
38. Sadreddini S, Seifi-Najimi M, Ghasemi B, Kafil HS, Alinejad V, Younesi V, **Jadidi-Niaragh F**, Yousefi M. Design and construction of immune phage antibody library against Tetanus neurotoxin: Production of single chain antibody fragment. *Human antibodies*, 2015; 23(3-4):73-79.
39. Haghighatfard H, Mansour Samaei N, Farazmandfar T, Ganjalikhani Hakemi M, Yamchi A, **Jadidi-Niaragh F**, Yazdani Y. Molecular Cloning and Expression of Novel Fibroblast Growth Factor-2 Conjugated with Immunodominant Domains of Pseudomonas exotoxin. *Biomedical and Pharmacology Journal*, 2015; 8(2): 1195-1200.
40. Hemmatzadeh M, Mohammadi H, **Jadidi-Niaragh F**, Asghari F, Yousefi M. The role of oncomirs in the pathogenesis and treatment of breast cancer. *Biomedicine & Pharmacotherapy*. 2016 Mar;78:129-39.
41. Safarzadeh E, **Jadidi-Niaragh F**, Motalebnezhad M, Yousefi M. The role of adenosine and adenosine receptors in the immunopathogenesis of multiple sclerosis. *Inflammation Research*. 2016 Jul;65(7):511-20.
42. Sadreddini S, **Jadidi-Niaragh F**, Younesi V, Poulak T, Afkham A, Shokri F, Yousefi M. Evaluation of EBV transformation of human memory B-cells isolated by FACS and MACS techniques. *Journal of Immunotoxicology*. 2016 Apr 4:1-8.
43. Dolati S, Sadreddini S, Rostamzadeh D, Ahmadi M, **Jadidi-Niaragh F**, Yousefi M. Utilization of nanoparticle technology in rheumatoid arthritis treatment. *Biomedicine & Pharmacotherapy*. 2016 May;80:30-41.
44. Khamisipour G, **Jadidi-Niaragh F**, Jahromi AS, Zandi K, Hojjat-Farsangi M. Mechanisms of tumor cell resistance to the current targeted-therapy agents. *Tumour Biology*. 2016 May 7.
45. Eivazy P, Atyabi F, **Jadidi-Niaragh F**, Aghebati Maleki L, Miahipour A, Abdolalizadeh J, Yousefi M. The impact of the codelivery of drug-siRNA by trimethyl chitosan nanoparticles on the efficacy of chemotherapy for metastatic breast cancer cell line (MDA-MB-231). *Artificial Cells, Nanomedicine and Biotechnology* 2016 May 17:1-8.
46. Siahmansouri H, Somi MH, Babaloo Z, Baradaran B, **Jadidi-Niaragh F**, Atyabi F, Mohammadi H, Ahmadi M, Yousefi M. Effects of HMGA2 siRNA and doxorubicin dual delivery by chitosan nanoparticles on cytotoxicity and gene expression of HT-29 colorectal cancer cell line. *Journal of Pharmacy and Pharmacology*. 2016 Jun 28.
47. Ghalamfarsa G, Hojjat-Farsangi M, Mohammadnia-Afrouzi M, Anvari E, Farhadi S, Yousefi M, **Jadidi-Niaragh F***. Application of nanomedicine for crossing the blood-brain barrier: Theranostic opportunities in multiple sclerosis. *Journal of Immunotoxicology*. 2016 Jul 14:1-17.
48. Motalebnezhad M, Aghebati-Maleki L, **Jadidi-Niaragh F**, Nickho H, Samadi-Kafil H, Shamsasenjan K, Yousefi M. The insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies. *Tumor Biology*. 2016 Jul 21.
49. Kheshtchin N, Arab S, Ajami M, Mirzaei R, Ashourpour M, Mousavi N, Khosravianfar N, **Jadidi-Niaragh F**, Namdar A, Noorbakhsh F, Hadjati J. Inhibition of HIF-1 α enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer. *Cancer Immunology Immunotherapy*. 2016 Aug 6.

50. Rostamzadeh D, Razavi SR, Esmaeili S, Dolati S, Ahmahi M, Sadreddini S, **Jadidi-Niaragh F**, Yousefi M. Application of nanoparticle technology in the treatment of Systemic lupus erythematosus. *Biomed Pharmacother*. 2016 Oct;83:1154-1163.
51. Motallebnezhad M, Aghebati-Maleki L, **Jadidi-Niaragh F**, Nickho H, Samadi-Kafil H, Shamsasenjan K, Yousefi M. The insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies. *Tumour Biol*. 2016 Sep;37(9):11711-11721.
52. Abdolmohammadi-Vahid S, Danaii S, Hamdi K, **Jadidi-Niaragh F**, Ahmadi M, Yousefi M.
Novel immunotherapeutic approaches for treatment of infertility. *Biomed Pharmacother*.. 2016 Dec;84:1449-1459.
53. Sadreddini S, Safaralizadeh R, Baradaran B, Aghebati-Maleki L, Hosseinpour-Feizi MA, Shanehbandi D, **Jadidi-Niaragh F**, Sadreddini S, Kafil HS, Younesi V, Yousefi M. Chitosan nanoparticles as a dual drug/siRNA delivery system for treatment of colorectal cancer. *Immunol Lett*. 2017 Jan;181:79-86.
54. **Jadidi-Niaragh F**, Atyabi F, Rastegari A, Kheshtchin N, Arab S, Hassannia H, Ajami M, Mirsanei Z, Habibi S, Masoumi F, Noorbakhsh F, Shokri F, Hadjati J. CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice. *J Control Release*. 2017 Jan 28;246:46-59.
55. Dolati S, Babaloo Z, **Jadidi-Niaragh F**, Ayromlou H, Sadreddini S, Yousefi M. Multiple sclerosis: Therapeutic applications of advancing drug delivery systems. *Biomed Pharmacother*. 2017 Feb;86:343-353.
56. Ghaebi M, Nouri M, Ghasemzadeh A, Farzadi L, **Jadidi-Niaragh F**, Ahmadi M, Yousefi M. Immune regulatory network in successful pregnancy and reproductive failures. *Biomed Pharmacother*. 2017 Jan 14;88:61-73.
57. Maleki LA, Younesi V, **Jadidi-Niaragh F**, Baradaran B, Majidi J, Yousefi M. Isolation and characterization of anti ROR1 single chain fragment variable antibodies using phage display technique. *Human Antibodies*. 2017 Jan 20.
58. Abbaszadeh-Goudarzi K, Shokri F, Hosseini M, **Jadidi-Niaragh F**, Ghalamfarsa G, Saboor-Yaraghi AA. Synergistic Induction of Apoptosis in B-CLL Cells after Treatment with All Trans Retinoic Acid in combination with IL21 and Rituximab. *Journal of Cancer Research and Therapeutic*. 2016 Oct-Dec;12(4):1278-1283.
59. Hosseini F, Hassannia H, Mahdian-Shakib A, **Jadidi-Niaragh F**, Enderami SE, Fattahi M, Anissian A, Mirshafiey A, Kokhaei P. Targeting of crosstalk between tumor and tumor microenvironment by β -D mannuronic acid (M2000) in murine breast cancer model. *Cancer Med*. 2017 Mar;6(3):640-650.
60. Kazemi MH, Raoofi Mohseni S, Hojjat-Farsangi M, Anvari E, Ghalamfarsa G, Mohammadi H, **Jadidi-Niaragh F***. Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer. *J Cell Physiol*. 2017 Feb 24. doi: 10.1002/jcp.25873
61. Arab S, Kheshtchin N, Ajami M, Ashurpoor M, Safvati A, Namdar A, Mirzaei R, Mousavi Niri N, **Jadidi-Niaragh F**, Ghahremani MH, Hadjati J. Increased efficacy of a dendritic cell-based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitor. *Tumour Biol*. 2017 Mar;39(3):1010428317695021.
62. Shali H, Shabani M, Pourgholi F, Hajivalili M, Aghebati-Maleki L, **Jadidi-Niaragh F**, Baradaran B, Movassaghpour Akbari AA, Younesi V, Yousefi M. Co-delivery of insulin-

like growth factor 1 receptor specific siRNA and doxorubicin using chitosan-based nanoparticles enhanced anticancer efficacy in A549 lung cancer cell line. *Artif Cells Nanomed Biotechnol.* 2017 Mar 31;1-10.

63. Safaie Qamsari E, Safaei Ghaderi S, Zarei B, Dorostkar R, Bagheri S, **Jadidi-Niaragh F**, Somi MH, Yousefi M. The c-Met receptor: Implication for targeted therapies in colorectal cancer. *Tumour Biol.* 2017 May;39(5):1010428317699118.
64. Ahmadi M, Abdolmohammadi-Vahid S, Ghaebi M, Aghebati-Maleki L, Afkham A, Danaii S, Abdollahi-Fard S, Heidari L, **Jadidi-Niaragh F**, Younesi V, Nouri M, Yousefi M. Effect of Intravenous immunoglobulin on Th1 and Th2 lymphocytes and improvement of pregnancy outcome in recurrent pregnancy loss (RPL). *Biomed Pharmacother.* 2017 Aug;92:1095-1102.
65. Bahrami B, Hojjat-Farsangi M, Mohammadi H, Anvari E, Ghalamfarsa G, Yousefi M, **Jadidi-Niaragh F***. Nanoparticles and targeted drug delivery in cancer therapy. *Immunol Lett.* 2017 Oct;190:64-83
66. Ahmadi M, Aghdam SA, Nouri M, Babaloo Z, Farzadi L, Ghasemzadeh A, Hamdi K, Movassaghpour AA, **Jadidi-Niaragh F**, Afkham A, Motalebnezhad M, Eghbal-Fard S, Dolati S, Younesi V, Yousefi M. Intravenous immunoglobulin (IVIG) treatment modulates peripheral blood Th17 and regulatory T cells in recurrent miscarriage patients: Non randomized, open-label clinical trial. *Immunol Lett.* 2017 Dec;192:12-19.
67. Mohammadi H, Sharafkandi N, Hemmatzadeh M, Azizi G, Karimi M, **Jadidi-Niaragh F***, Baradaran B, Babaloo Z. The Role of Innate lymphoid cells in health and disease. *J Cell Physiol.* 2017 Oct 23.
68. Asadzadeh Z, Mohammadi H, Safarzadeh E, Hemmatzadeh M, Mahdian-Shakib A, **Jadidi-Niaragh F**, Azizi G, Baradaran B. The paradox of Th17 cell functions in tumor immunity. *Cell Immunol.* 2017 Oct 31. pii: S0008-8749(17)30191-0.
69. Hassannia H, Amiri MM, **Jadidi-Niaragh F**, Hosseini-Ghatar R, Khoshnoodi J, Sharifian RA, Golsaz-Shirazi F, Jeddi-Tehrani M, Shokri F. Inhibition of tumor growth by mouse ROR1 specific antibody in a syngeneic mouse tumor model. *Immunol Lett.* 2018 Jan;193:35-41.
70. Naimi A, Movassaghpour AA, Hagh MF, Talebi M, Entezari A, **Jadidi-Niaragh F**, Solali S. TNF-related apoptosis-inducing ligand (TRAIL) as the potential therapeutic target in hematological malignancies. *Biomed Pharmacother.* 2017 Dec 27;98:566-576.
71. Afkari B, Babaloo Z, Dolati S, Khabazi A, **Jadidi-Niaragh F**, Talei M, Shanehbandi D, Mahmoudi S, Hazhirkarzar B, Sakhinia E. Molecular analysis of interleukin-10 gene polymorphisms in patients with Behçet's disease. *Immunol Lett.* 2017 Dec 30;194:56-61.
72. Dolati S, Ahmadi M, Khalili M, Taheraghdam AA, Siahmansouri H, Babaloo Z, Aghebati-Maleki L, **Jadidi-Niaragh F**, Younesi V, Yousefi M. Peripheral Th17/Treg imbalance in elderly patients with ischemic stroke. *Neurol Sci.* 2018 Apr;39(4):647-654. doi: 10.1007/s10072-018-3250-4
73. Ranjbar R, Karimian A, Aghaie Fard A, Tourani M, Majidinia M, **Jadidi-Niaragh F**, Yousefi B. The importance of miRNAs and epigenetics in acute lymphoblastic leukemia prognosis. *J Cell Physiol.* 2019 Apr;234(4):3216-3230. doi: 10.1002/jcp.26510.
74. Sheikhsari G, Aghebati-Maleki L, Nouri M, **Jadidi-Niaragh F**, Yousefi M. Current approaches for the treatment of premature ovarian failure with stem cell therapy. *Biomed Pharmacother.* 2018 Jun;102:254-262. doi: 10.1016/j.biopha.2018.03.056.

75. Hosseini F, Mahdian-Shakib A, **Jadidi-Niaragh F**, Enderami SE, Mohammadi H, Hemmatzadeh M, Mohammed HA, Anissian A, Kokhaei P, Mirshafiey A, Hassannia H. Anti-inflammatory and anti-tumor effects of α -L-guluronic acid (G2013) on cancer-related inflammation in a murine breast cancer model. *Biomed Pharmacother*. 2018 Feb;98:793-800. doi: 10.1016/j.biopha.2017.12.111.
76. Azizi G, Kiaee F, Hedayat E, Yazdani R, Dolatshahi E, Alinia T, Sharifi L, Mohammadi H, Kavosi H, **Jadidi-Niaragh F**, Ziaee V, Abolhassani H, Aghamohammadi A. Rheumatologic complications in a cohort of 227 patients with common variable immunodeficiency. *Scand J Immunol*. 2018 May;87(5):e12663. doi: 10.1111/sji.12663.
77. Afkham A, Aghebati-Maleki L, Siahmansouri H, Sadreddini S, Ahmadi M, Dolati S, Afkham NM, Akbarzadeh P, **Jadidi-Niaragh F**, Younesi V, Yousefi M. Chitosan (CMD)-mediated co-delivery of SN38 and Snail-specific siRNA as a useful anticancer approach against prostate cancer. *Pharmacol Rep*. 2018 Jun;70(3):418-425. doi: 10.1016/j.pharep.2017.11.005.
78. Ghalamfarsa G, Rastegari A, Atyabi F, Hassannia H, Hojjat-Farsangi M, Ghanbari A, Anvari E, Mohammadi J, Azizi G, Masjedi A, Yousefi M, Yousefi B, Hadjati J, **Jadidi-Niaragh F***. Anti-angiogenic effects of CD73-specific siRNA-loaded nanoparticles in breast cancer-bearing mice. *J Cell Physiol*. 2018 Oct;233(10):7165-7177. doi: 10.1002/jcp.26743.
79. Jafari R, Majidi Zolbanin N, Majidi J, Atyabi F, Yousefi M, **Jadidi-Niaragh F**, Aghebati-Maleki L, Shanehbandi D, Soltani Zangbar MS, Rafatpanah H. Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1R siRNA to SKBR3 Metastatic Breast Cancer Cells. *Iran Biomed J*. 2019 Jan;23(1):21-33.
80. Azizi G, Bagheri Y, Yazdani R, Zaki-Dizaji M, Jamee M, **Jadidi-Niaragh F**, Kamali AN, Abolhassani H, Aghamohammadi A. The profile of IL-4, IL-5, IL-10 and GATA3 in patients with LRBA deficiency and CVID with no known monogenic disease: Association with disease severity. *Allergol Immunopathol (Madr)*. 2018 Sep 4. pii: S0301-0546(18)30101-0. doi: 10.1016/j.aller.2018.06.003.
81. Heydarlou H, Eghabl-Fard S, Ahmadi M, Aghebati-Maleki L, Dolati S, Movassaghpour AA, **Jadidi-Niaragh F**, Danaei S, Mahmoudilafout F, Talebi M, Rahimifar S, Yousefi M. Investigation of follicular helper T cells, as a novel player, in preeclampsia. *J Cell Biochem*. 2019 Mar;120(3):3845-3852. doi: 10.1002/jcb.27666.
82. Majidi Zolbanin N, Jafari R, Majidi J, Atyabi F, Yousefi M, **Jadidi-Niaragh F**, Aghebati-Maleki L, Shanehbandi D, Soltani Zangbar MS, Nayebi AM. Targeted Co-Delivery of Docetaxel and cMET siRNA for Treatment of Mucin1 Overexpressing Breast Cancer Cells. *Adv Pharm Bull*. 2018 Aug;8(3):383-393. doi: 10.15171/apb.2018.045.
83. Eghbal-Fard S, Yousefi M, Heydarlou H, Ahmadi M, Taghavi S, Movasaghpour A, **Jadidi-Niaragh F**, Yousefi B, Dolati S, Hojjat-Farsangi M, Rikhtegar R, Nouri M, Aghebati-Maleki L. The imbalance of Th17/Treg axis involved in the pathogenesis of preeclampsia. *J Cell Physiol*. 2019 Apr;234(4):5106-5116. doi: 10.1002/jcp.27315.
84. Hashemi V, Farrokhi AS, Tanomand A, Babaloo Z, Hojjat-Farsangi M, Anvari E, Tahoori MT, Ezzeddini R, Hosseini A, Gharibi T, Ghalamfarsa G, **Jadidi-Niaragh F***. Polymorphism of Foxp3 gene affects the frequency of regulatory T cells and disease activity in patients with rheumatoid arthritis in Iranian population. *Immunol Lett*. 2018 Dec;204:16-22. doi: 10.1016/j.imlet.2018.10.001.

85. Jafarzadeh S, Ahmadi M, Dolati S, Aghebati-Maleki L, Eghbal-Fard S, Kamrani A, Behrad B, Roshangar L, **Jadidi-Niaragh F**, Yousefi B, Mehdipour M, Farzadi L, Yousefi M. Intravenous immunoglobulin G treatment increases live birth rate in women with recurrent miscarriage and modulates regulatory and exhausted regulatory T cells frequency and function. *J Cell Biochem*. 2018 Oct 16. doi: 10.1002/jcb.27821.
86. Masjedi A, Hashemi V, Hojjat-Farsangi M, Ghalamfarsa G, Azizi G, Yousefi M, **Jadidi-Niaragh F***. The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. *Biomed Pharmacother*. 2018 Dec;108:1415-1424. doi: 10.1016/j.biopha.2018.09.177.
87. Hashemi V, Masjedi A, Hazhir-Karzar B, Tanomand A, Shotorbani SS, Hojjat-Farsangi M, Ghalamfarsa G, Azizi G, Anvari E, Baradaran B, **Jadidi-Niaragh F***. The role of DEAD-box RNA helicase p68 (DDX5) in the development and treatment of breast cancer. *J Cell Physiol*. 2018 Nov 11. doi: 10.1002/jcp.26912.
88. Talei M, Abdi A, Shanebandi D, **Jadidi-Niaragh F**, Khabazi A, Babaie F, Alipour S, Afkari B, Sakhinia E, Babaloo Z. Interleukin-33 Gene expression and rs1342326 Polymorphism in Behçet's Disease. *Immunol Lett*. 2018 Nov 14. pii: S0165-2478(17)30443-1. doi: 10.1016/j.imlet.2018.11.005.
89. Ghaebi M, Abdolmohammadi-Vahid S, Ahmadi M, Eghbal-Fard S, Dolati S, Nouri M, Talebi M, Hamdi K, Marofi F, Aghebati-Maleki L, **Jadidi-Niaragh F**, Dopour M, Yousefi M. T cell Subsets in Peripheral Blood of Women with Recurrent Implantation Failure. *J Reprod Immunol*. 2018 Nov 8;131:21-29. doi: 10.1016/j.jri.2018.11.002.
90. Kamali AN, Noorbakhsh SM, Hamedifar H, **Jadidi-Niaragh F**, Yazdani R, Bautista JM, Azizi G. A role for Th1-like Th17 cells in the pathogenesis of inflammatory and autoimmune disorders. *Mol Immunol*. 2019 Jan;105:107-115. doi: 10.1016/j.molimm.2018.11.015
91. Nikkhoo A, Rostami N, Hojjat-Farsangi M, Azizi G, Yousefi B, Ghalamfarsa G, **Jadidi-Niaragh F***. Smac mimetics as novel promising modulators of apoptosis in the treatment of breast cancer. *J Cell Biochem*. 2018 Dec 3. doi: 10.1002/jcb.28205.
92. Azizi G, Jamee M, Yazdani R, Bagheri Y, Fayyaz F, **Jadidi-Niaragh F**, Abolhassani H, Aghamohammadi A. CTLA-4 Expression in CD4+ T Cells From Patients With LRBA Deficiency and Common Variable Immunodeficiency With No Known Monogenic Disease. *J Investig Allergol Clin Immunol*. 2018 Dec;28(6):422-424. doi: 10.18176/jiaci.0302.
93. Hosseini A, Masjedi A, Baradaran B, Hojjat-Farsangi M, Ghalamfarsa G, Anvari E, **Jadidi-Niaragh F***. Dimethyl fumarate: Regulatory effects on the immune system in the treatment of multiple sclerosis. *J Cell Physiol*. 2018 Dec 7. doi: 10.1002/jcp.27930.
94. Ghalamfarsa G, Kazemi MH, Raoofi Mohseni S, Masjedi A, Hojjat-Farsangi M, Azizi G, Yousefi M, **Jadidi-Niaragh F***. CD73 as a potential opportunity for cancer immunotherapy. *Expert Opin Ther Targets*. 2019 Feb;23(2):127-142. doi: 10.1080/14728222.2019.1559829.
95. Azizi R, Ahmadi M, Danaii S, Abdollahi-Fard S, Mosapour P, Eghbal-Fard S, Dolati S, Kamrani A, Rahnama B, Mehdizadeh A, **Jadidi-Niaragh F**, Yousefi B, Yousefi M. Cyclosporine A improves pregnancy outcomes in women with recurrent pregnancy loss and elevated Th1/Th2 ratio. *J Cell Physiol*. 2019 Mar 28. doi: 10.1002/jcp.28543.

96. Masjedi A, Hassannia H, Atyabi F, Rastegari A, Hojjat-Farsangi M, Namdar A, Soleimanpour H, Azizi G, Nikkhoo A, Ghalamfarsa G, Mirshafiey A, **Jadidi-Niaragh F***. Downregulation of A2AR by siRNA loaded PEG-chitosan-lactate nanoparticles restores the T cell mediated anti-tumor responses through blockage of PKA/CREB signaling pathway. *Int J Biol Macromol*. 2019 Mar 30;133:436-445. doi: 10.1016/j.ijbiomac.2019.03.223.
97. Mortazavi H, Soltani-Zangbar MS, Eghbal-Fard S, Mehdizadeh A, Kamrani A, Chakeri-Khiavi F, Kafil HS, **Jadidi-Niaragh F**, Rahimifar S, Khosroshahi HT, Yousefi M. Cytokine profile, Treg/Th17 cell frequency changes during different posttransplantational time points in patients undergoing renal transplantation. *J Cell Physiol*. 2019 Apr 22. doi: 10.1002/jcp.28698.
98. Mashayekhi S, Yousefi B, Tohidi E, Darband SG, Mirza-Aghazadeh-Attari M, Sadighparvar S, Kaviani M, Shafiei-Irannejad V, Kafil HS, Karimian A, **Jadidi-Niaragh F**, Majidinia M. Overexpression of tensin homolog deleted on chromosome ten (PTEN) by ciglitazone sensitizes doxorubicin-resistance leukemia cancer cells to treatment. *J Cell Biochem*. 2019 May 14. doi: 10.1002/jcb.28841.
99. Karpisheh V, Nikkhoo A, Hojjat-Farsangi M, Namdar A, Azizi G, Ghalamfarsa G, Yousefi M, Yousefi B, **Jadidi-Niaragh F***. Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer. *Prostaglandins Other Lipid Mediat*. 2019 May 14;106338. doi: 10.1016/j.prostaglandins.2019.106338.
100. Jamee M, Moniri S, Zaki-Dizaji M, Olbrich P, Yazdani R, **Jadidi-Niaragh F**, Aghamahdi F, Abolhassani H, Condliffe AM, Aghamohammadi A, Azizi G. Clinical, Immunological, and Genetic Features in Patients with Activated PI3K δ Syndrome (APDS): a Systematic Review. *Clin Rev Allergy Immunol*. 2019 May 21. doi: 10.1007/s12016-019-08738-9.
101. Rostami N, Nikkhoo A, Ajjoolabady A, Azizi G, Hojjat-Farsangi M, Ghalamfarsa G, Yousefi B, Yousefi M, **Jadidi-Niaragh F***. S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy. *Mol Diagn Ther*. 2019 May 21. doi: 10.1007/s40291-019-00401-5.
102. Koushaeian L, Ghorbani F, Ahmadi M, Eghbal-Fard S, Zamani M, Danaii S, Yousefi B, **Jadidi-Niaragh F**, Hamdi K, Yousefi M. The role of IL-10-producing B cells in repeated implantation failure patients with cellular immune abnormalities. *Immunol Lett*. 2019 Oct;214:16-22. doi: 10.1016/j.imlet.2019.08.002.
103. Hosseini SM, Okoye I, Chaleshtari MG, Hazhirkarzar B, Mohamadnejad J, Azizi G, Hojjat-Farsangi M, Mohammadi H, Shotorbani SS, **Jadidi-Niaragh F***. E2 ubiquitin-conjugating enzymes in cancer: Implications for immunotherapeutic interventions. *Clin Chim Acta*. 2019 Nov;498:126-134. doi: 10.1016/j.cca.2019.08.020.
104. Hallaj S, Meshkini F, Chaleshtari MG, Ghorbani A, Namdar A, Soleimanpour H, **Jadidi-Niaragh F***. Conjugated CAR T cell one step beyond conventional CAR T cell for a promising cancer immunotherapy. *Cell Immunol*. 2019 Nov;345:103963. doi: 10.1016/j.cellimm.2019.103963.
105. Kiaee F, Azizi G, Rafiemanesh H, Zainaldain H, Sadaat Rizvi F, Alizadeh M, Jamee M, Mohammadi S, Habibi S, Sharifi L, **Jadidi-Niaragh F**, Haghi S, Yazdani R, Abolhassani H, Aghamohammadi A. Malignancy in common variable immunodeficiency: a systematic review and meta-analysis. *Expert Rev Clin Immunol*. 2019 Oct;15(10):1105-1113. doi: 10.1080/1744666X.2019.1658523.

106. Tavakol M, Jamee M, Azizi G, Sadri H, Bagheri Y, Zaki-Dizaji M, Mahdavi FS, **Jadidi-Niaragh F**, Tajfirooz S, Kamali AN, Aghamahdi F, Noorian S, Kojidi HT, Mosavian M, Matani R, Dolatshahi E, Porrostami K, Elahimehr N, Fatemi-Abhari M, Sharifi L, Arjmand R, Haghi S, Zainaldain H, Yazdani R, Shaghaghi M, Abolhassani H, Aghamohammadi A. Diagnostic Approach to The Patients with Suspected Primary Immunodeficiency. *Endocr Metab Immune Disord Drug Targets*. 2019 Aug 28. doi: 10.2174/1871530319666190828125316.
107. **Jadidi-Niaragh F***. Potential of CD73 as a target for cancer immunotherapy. *Immunotherapy*. 2019 Nov;11(16):1353-1355. doi: 10.2217/imt-2019-0147.
108. Hassannia H, Ghasemi Chaleshtari M, Atyabi F, Nosouhian M, Masjedi A, Hojjat-Farsangi M, Namdar A, Azizi G, Mohammadi H, Ghalamfarsa G, Sabz G, Hasanzadeh S, Yousefi M, **Jadidi-Niaragh F***. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine. *Immunology*. 2019 Oct 6. doi: 10.1111/imm.13126.
109. Hajizadeh F, Okoye I, Esmaily M, Ghasemi Chaleshtari M, Masjedi A, Azizi G, Irandoust M, Ghalamfarsa G, **Jadidi-Niaragh F***. Hypoxia inducible factors in the tumor microenvironment as therapeutic targets of cancer stem cells. *Life Sci*. 2019 Nov 15;237:116952. doi: 10.1016/j.lfs.2019.116952.
110. Abolghasemi M, Tehrani SS, Yousefi T, Karimian A, Mahmoodpoor A, Ghamari A, **Jadidi-Niaragh F**, Yousefi M, Kafil HS, Bastami M, Edalati M, Eyvazi S, Naghizadeh M, Targhazeh N, Yousefi B, Safa A, Majidinia M, Rameshknia V. MicroRNAs in breast cancer: Roles, functions, and mechanism of actions. *J Cell Physiol*. 2019 Nov 14. doi: 10.1002/jcp.29396.
111. Pourgholi F, Hajivalili M, **Jadidi-Niaragh F**, Kafil HS, Yousefi M. Nanoparticles: Novel vehicles in treatment of Glioblastoma. *Biomed Pharmacother*. 2016 Feb;77:98-107. doi: 10.1016/j.biopha.2015.12.014.
112. Mousavi Niri N1, Memarnejadian A, Pilehvar-Soltanahmadi Y, Agha Sadeghi M, Mahdavi M, Kheshtchin N, Arab S, Namdar A, **Jadidi F**, Zarghami N, Hajati J. Improved Anti-Treg Vaccination Targeting Foxp3 Efficiently Decreases Regulatory T Cells in Mice. *J Immunother*. 2016 Sep;39(7):269-75. doi: 10.1097/CJI.0000000000000133.
113. Hossein-Khannazer N, Azizi G, Eslami S, Alhassan Mohammed H, Fayyaz F, Hosseinzadeh R, Usman AB, Kamali AN, Mohammadi H, **Jadidi-Niaragh F**, Dehghanifard E, Noorisepehr M. The effects of cadmium exposure in the induction of inflammation. *Immunopharmacol Immunotoxicol*. 2020 Feb;42(1):1-8.
114. Ramzi N, Jamee M, Bakhtiyari M, Rafiemanesh H, Zainaldain H, Tavakol M, Rezaei A, Kalvandi M, Zian Z, Mohammadi H, **Jadidi-Niaragh F**, Yazdani R, Abolhassani H, Aghamohammadi A, Azizi G. Bronchiectasis in common variable immunodeficiency: A systematic review and meta-analysis. *Bronchiectasis in common variable immunodeficiency: A systematic review and meta-analysis*. *Pediatr Pulmonol*. 2020 Feb;55(2):292-299.
115. Hashemi V, Maleki LA, Esmaily M, Masjedi A, Ghalamfarsa G, Namdar A, Yousefi M, Yousefi B, **Jadidi-Niaragh F***. Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target. *Int Immunopharmacol*. 2020 Jan;78:106087. doi: 10.1016/j.intimp.2019.106087.

116. Abolghasemi M, Tehrani SS, Yousefi T, Karimian A, Mahmoodpoor A, Ghamari A, **Jadidi-Niaragh F**, Yousefi M, Kafil HS, Bastami M, Edalati M, Eyvazi S, Naghizadeh M, Targhazeh N, Mihanfar A, Yousefi B, Safa A, Majidinia M, Rameshknia V. Critical roles of long noncoding RNAs in breast cancer. *J Cell Physiol*. 2020 Jun;235(6):5059-5071. doi: 10.1002/jcp.29442.
117. Pishgahi A, Abolhasan R, Danaii S, Amanifar B, Soltani-Zangbar MS, Zamani M, Kamrani A, Ghorbani F, Mehdizadeh A, Kafil HS, **Jadidi-Niaragh F**, Yousefi B, Hajialiloo M, Yousefi M. Immunological and oxidative stress biomarkers in Ankylosing Spondylitis patients with or without metabolic syndrome. *Cytokine*. 2020 Apr;128:155002. doi: 10.1016/j.cyto.2020.155002
118. Masjedi A, Ahmadi A, Atyabi F, Farhadi S, Irandoust M, Khazaei-Poul Y, Ghasemi Chaleshtari M, Edalati Fathabad M, Baghaei M, Haghnava N, Baradaran B, Hojjat-Farsangi M, Ghalamfarsa G, Sabz G, Hasanzadeh S, **Jadidi-Niaragh F***. Silencing of IL-6 and STAT3 by siRNA loaded hyaluronate-N,N,N-trimethyl chitosan nanoparticles potently reduces cancer cell progression. *Int J Biol Macromol*. 2020 Apr 15;149:487-500. doi: 10.1016/j.ijbiomac.2020.01.273.
119. Jafari S, Molavi O, Kahroba H, Hejazi MS, Maleki-Dizaji N, Barghi S, Kiaie SH, **Jadidi-Niaragh F**. Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer. *Cell Mol Life Sci*. 2020 Oct;77(19):3693-3710. doi: 10.1007/s00018-020-03459-1.
120. Izadi S, Nikkhoo A, Hojjat-Farsangi M, Namdar A, Azizi G, Mohammadi H, Yousefi M, **Jadidi-Niaragh F***. CDK1 in Breast Cancer: Implications for Theranostic Potential. *Anticancer Agents Med Chem*. 2020;20(7):758-767. doi: 10.2174/1871520620666200203125712.
121. Bastaki S, Irandoust M, Ahmadi A, Hojjat-Farsangi M, Ambrose P, Hallaj S, Edalati M, Ghalamfarsa G, Azizi G, Yousefi M, Chalajour H, **Jadidi-Niaragh F***. PD-L1/PD-1 axis as a potent therapeutic target in breast cancer. *Life Sci*. 2020 Apr 15;247:117437. doi: 10.1016/j.lfs.2020.117437.
122. Babaie F, Hosseinzadeh R, Ebrazeh M, Seyfizadeh N, Aslani S, Salimi S, Hemmatzadeh M, Azizi G, **Jadidi-Niaragh F**, Mohammadi H. The roles of ERAP1 and ERAP2 in autoimmunity and cancer immunity: New insights and perspective. *Mol Immunol*. 2020 May;121:7-19. doi: 10.1016/j.molimm.2020.02.020.
123. Salimifard S, Masjedi A, Hojjat-Farsangi M, Ghalamfarsa G, Irandoust M, Azizi G, Mohammadi H, Keramati MR, **Jadidi-Niaragh F***. Cancer associated fibroblasts as novel promising therapeutic targets in breast cancer. *Pathol Res Pract*. 2020 May;216(5):152915. doi: 10.1016/j.prp.2020.152915.
124. Nikkhoo A, Rostami N, Farhadi S, Esmaily M, Moghadaszadeh Ardebili S, Atyabi F, Baghaei M, Haghnava N, Yousefi M, Aliparasti MR, Ghalamfarsa G, Mohammadi H, Sojoodi M, **Jadidi-Niaragh F***. Codelivery of STAT3 siRNA and BV6 by carboxymethyl dextran trimethyl chitosan nanoparticles suppresses cancer cell progression. *Int J Pharm*. 2020 May 15;581:119236. doi: 10.1016/j.ijpharm.2020.119236
125. Hashemi V, Farhadi S, Ghasemi Chaleshtari M, Seashore-Ludlow B, Masjedi A, Hojjat-Farsangi M, Namdar A, Ajjoolabady A, Mohammadi H, Ghalamfarsa G, **Jadidi-Niaragh F***. Nanomedicine for improvement of dendritic cell-based cancer immunotherapy. *Int Immunopharmacol*. 2020 Jun;83:106446. doi: 10.1016/j.intimp.2020.106446

126. Yousefzadeh Y, Hallaj S, Baghi Moornani M, Asghary A, Azizi G, Hojjat-Farsangi M, Ghalamfarsa G, **Jadidi-Niaragh F***. Tumor associated macrophages in the molecular pathogenesis of ovarian cancer. *Int Immunopharmacol*. 2020 Jul;84:106471. doi: 10.1016/j.intimp.2020.106471.
127. LBD Double Burden of Malnutrition Collaborators. Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017. *Nat Med*. 2020 May;26(5):750-759. doi: 10.1038/s41591-020-0807-6.
128. Ebrazeh M, Nojavan M, Abdi-Shayan S, Salimifard S, Dolatshahi E, Aslani S, Hemmatzadeh M, Babaie F, Ghanavatinejad A, Azizi G, **Jadidi-Niaragh F**, Zamani N, Mohammadi H. Endoplasmic reticulum aminopeptidase 2 gene single nucleotide polymorphisms in association with susceptibility to ankylosing spondylitis in an Iranian population. *Immunol Lett*. 2020 Jul;223:97-105. doi: 10.1016/j.imlet.2020.04.015.
129. Mirsanei Z, Habibi S, Kheshtchin N, Mirzaei R, Arab S, Zand B, **Jadidi-Niaragh F**, Safvati A, Sharif-Paghaleh E, Arabameri A, Asemani D, Hajati J. Optimized Dose of Dendritic Cell-based Vaccination in Experimental Model of Tumor Using Artificial Neural Network. *Iran J Allergy Asthma Immunol*. 2020 Apr 16;19(2):172-182. doi: 10.18502/ijaa.v19i2.2770.
130. Hemmat N, Mokhtarzadeh A, Aghazadeh M, **Jadidi-Niaragh F**, Baradaran B, Bannazadeh Baghi H. Role of microRNAs in epidermal growth factor receptor signaling pathway in cervical cancer. *Mol Biol Rep*. 2020 Jun;47(6):4553-4568. doi: 10.1007/s11033-020-05494-4.
131. Danbaran GR, Aslani S, Sharafkandi N, Hemmatzadeh M, Hosseinzadeh R, Azizi G, **Jadidi-Niaragh F**, Babaie F, Mohammadi H. How microRNAs affect the PD-L1 and its synthetic pathway in cancer. *Int Immunopharmacol*. 2020 Jul;84:106594. doi: 10.1016/j.intimp.2020.106594.
132. Jamee M, Zaki-Dizaji M, Lo B, Abolhassani H, Aghamahdi F, Mosavian M, Nademi Z, Mohammadi H, **Jadidi-Niaragh F**, Rojas M, Anaya JM, Azizi G. Clinical, Immunological, and Genetic Features in Patients with Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) and IPEX-like Syndrome. *J Allergy Clin Immunol Pract*. 2020 Sep;8(8):2747-2760.e7. doi: 10.1016/j.jaip.2020.04.070.
133. Sharifinejad N, Jamee M, Zaki-Dizaji M, Lo B, Shaghaghi M, Mohammadi H, **Jadidi-Niaragh F**, Shaghaghi S, Yazdani R, Abolhassani H, Aghamohammadi A, Azizi G. Clinical, Immunological, and Genetic Features in 49 Patients With ZAP-70 Deficiency: A Systematic Review. *Front Immunol*. 2020 May 5;11:831. doi: 10.3389/fimmu.2020.00831.
134. Ghasemi-Chaleshtari M, Kiaie SH, Irandoust M, Karami H, Nabi Afjadi M, Ghani S, Aghaei Vanda N, Ghaderi Sede MJ, Ahmadi A, Masjedi A, Hassannia H, Atyabi F, Hojjat-Farsangi M, Namdar A, Ghalamfarsa G, **Jadidi-Niaragh F***. Concomitant blockade of A2AR and CTLA-4 by siRNA-loaded polyethylene glycol-chitosan-alginate nanoparticles synergistically enhances antitumor T-cell responses. *J Cell Physiol*. 2020 Dec;235(12):10068-10080. doi: 10.1002/jcp.29822.
135. Kiaee F, Zaki-Dizaji M, Hafezi N, Almasi-Hashiani A, Hamedifar H, Sabzevari A, Shirvani A, Zian Z, **Jadidi-Niaragh F**, Aghamahdi F, Goudarzvand M, Yazdani R, Abolhassani H, Aghamohammadi A, Azizi G. Clinical, Immunologic and Molecular Spectrum of Patients with Immunodeficiency, Centromeric Instability, and Facial

- Anomalies (ICF) Syndrome: A Systematic Review. *Endocr Metab Immune Disord Drug Targets*. 2021;21(4):664-672. doi: 10.2174/1871530320666200613204426.
136. Masjedi A, Ahmadi A, Ghani S, Malakotikhah F, Nabi Afjadi M, Irandoust M, Karoon Kiani F, Heydarzadeh Asl S, Atyabi F, Hassannia H, Hojjat-Farsangi M, Namdar A, Ghalamfarsa G, **Jadidi-Niaragh F***. Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy. *Nanomedicine*. 2020 Oct;29:102240. doi: 10.1016/j.nano.2020.102240.
 137. Hajizadeh F, Moghadaszadeh Ardebili S, Baghi Moornani M, Masjedi A, Atyabi F, Kiani M, Namdar A, Karpisheh V, Izadi S, Baradaran B, Azizi G, Ghalamfarsa G, Sabz G, Yousefi M, **Jadidi-Niaragh F***. Silencing of HIF-1 α /CD73 axis by siRNA-loaded TAT-chitosan-spion nanoparticles robustly blocks cancer cell progression. *Eur J Pharmacol*. 2020 Sep 5;882:173235. doi: 10.1016/j.ejphar.2020.173235.
 138. Esmaily M, Masjedi A, Hallaj S, Nabi Afjadi M, Malakotikhah F, Ghani S, Ahmadi A, Sojoodi M, Hassannia H, Atyabi F, Namdar A, Azizi G, Ghalamfarsa G, **Jadidi-Niaragh F***. Blockade of CTLA-4 increases anti-tumor response inducing potential of dendritic cell vaccine. *J Control Release*. 2020 Oct 10;326:63-74. doi: 10.1016/j.jconrel.2020.06.017.
 139. Ghaderian S, Shomali N, Behravesheh S, Danbaran GR, Hemmatzadeh M, Aslani S, **Jadidi-Niaragh F**, Hosseinzadeh R, Torkamandi S, Mohammadi H. The emerging role of lncRNAs in multiple sclerosis. *J Neuroimmunol*. 2020 Oct 15;347:577347. doi: 10.1016/j.jneuroim.2020.577347.
 140. Hajizadeh F, Masjedi A, Heydarzadeh Asl S, Karoon Kiani F, Peydaveisi M, Ghalamfarsa G, **Jadidi-Niaragh F***, Sevbitov A. Adenosine and adenosine receptors in colorectal cancer. *Int Immunopharmacol*. 2020 Oct;87:106853. doi: 10.1016/j.intimp.2020.106853.
 141. Lotfinejad P, Kazemi T, Mokhtarzadeh A, Shanehbandi D, **Jadidi Niaragh F**, Safaei S, Asadi M, Baradaran B. PD-1/PD-L1 axis importance and tumor microenvironment immune cells. *Life Sci*. 2020 Oct 15;259:118297. doi: 10.1016/j.lfs.2020.118297.
 142. Maleki M, Khelghati N, Alemi F, Bazdar M, Asemi Z, Majidinia M, Sadeghpour A, Mahmoodpour A, Jadidi-Niaragh F, Targhazeh N, Yousefi B. Stabilization of telomere by the antioxidant property of polyphenols: Anti-aging potential. *Life Sci*. 2020 Oct 15;259:118341. doi: 10.1016/j.lfs.2020.118341.
 143. GBD 2019 Universal Health Coverage Collaborators. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020 Oct 17;396(10258):1250-1284. doi: 10.1016/S0140-6736(20)30750-9.
 144. Hallaj S, Ghorbani A, Mousavi-Aghdas SA, Mirza-Aghazadeh-Attari M, Sevbitov A, Hashemi V, Hallaj T, **Jadidi-Niaragh F***. Angiotensin-converting enzyme as a new immunologic target for the new SARS-CoV-2. *Immunol Cell Biol*. 2021 Feb;99(2):192-205. doi: 10.1111/imcb.12396.
 145. Sadeghi A, Tahmasebi S, Mahmood A, Kuznetsova M, Valizadeh H, Taghizadieh A, Nazemiyeh M, Aghebati-Maleki L, **Jadidi-Niaragh F**, Abbaspour-Aghdam S, Roshangar L, Mikaeili H, Ahmadi M. Th17 and Treg cells function in SARS-CoV2

- patients compared with healthy controls. *J Cell Physiol.* 2021 Apr;236(4):2829-2839. doi: 10.1002/jcp.30047.
146. Lotfinejad P, Asghari Jafarabadi M, Abdoli Shadbad M, Kazemi T, Pashazadeh F, Sandoghchian Shotorbani S, **Jadidi Niaragh F**, Baghbanzadeh A, Vahed N, Silvestris N, Baradaran B. Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study. *Diagnostics (Basel).* 2020 Sep 17;10(9):704. doi: 10.3390/diagnostics10090704.
 147. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet.* 2020 Oct 17;396(10258):1204-1222. doi: 10.1016/S0140-6736(20)30925-9.
 148. Alzamely KO, Hajizadeh F, Heydari M, Ghaderi Sede MJ, Asl SH, Peydaveisi M, Masjedi A, Izadi S, Nikkhoo A, Atyabi F, Namdar A, Baradaran B, Sojoodi M, **Jadidi-Niaragh F***. Combined inhibition of CD73 and ZEB1 by Arg-Gly-Asp (RGD)-targeted nanoparticles inhibits tumor growth. *Colloids Surf B Biointerfaces.* 2021 Jan;197:111421. doi: 10.1016/j.colsurfb.2020.111421.
 149. Hajizadeh F, Aghebati Maleki L, Alexander M, Mikhailova MV, Masjedi A, Ahmadpour M, Hashemi V, **Jadidi-Niaragh F***. Tumor-associated neutrophils as new players in immunosuppressive process of the tumor microenvironment in breast cancer. *Life Sci.* 2021 Jan 1;264:118699. doi: 10.1016/j.lfs.2020.118699. Epub 2020 Oct 31.
 150. Masjedi A, Hajizadeh F, Beigi Dargani F, Beyzai B, Aksoun M, Hojjat-Farsangi M, Zekiy A, **Jadidi-Niaragh F***. Oncostatin M: A mysterious cytokine in cancers. *Int Immunopharmacol.* 2021 Jan;90:107158. doi: 10.1016/j.intimp.2020.107158.
 151. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. GBD 2019 Universal Health Coverage Collaborators. *Lancet.* 2020 Oct 17;396(10258):1250-1284. doi: 10.1016/S0140-6736(20)30750-9. Epub 2020 Aug 27.
 152. Karpisheh V, Joshi N, Zekiy AO, Beyzai B, Hojjat-Farsangi M, Namdar A, Edalati M, **Jadidi-Niaragh F***. EP4 receptor as a novel promising therapeutic target in colon cancer. *Pathol Res Pract.* 2020 Dec;216(12):153247. doi: 10.1016/j.prp.2020.153247.
 153. Karpisheh V, Fakkari Afjadi J, Nabi Afjadi M, Haeri MS, Abdpoor Sough TS, Heydarzadeh Asl S, Edalati M, Atyabi F, Masjedi A, Hajizadeh F, Izadi S, Mirzazadeh Tekie FS, Hajiramezanali M, Sojoodi M, **Jadidi-Niaragh F***. Inhibition of HIF-1 α /EP4 axis by hyaluronate-trimethyl chitosan-SPION nanoparticles markedly suppresses the growth and development of cancer cells. *Int J Biol Macromol.* 2021 Jan 15;167:1006-1019. doi: 10.1016/j.ijbiomac.2020.11.056.
 154. Ebrahimi N, Aslani S, Babaie F, Hemmatzadeh M, Pourmoghadam Z, Azizi G, Jadidi-Niaragh F, Mohammadi H. MicroRNAs Implications in the Onset, Diagnosis, and Prognosis of Osteosarcoma. *Curr Mol Med.* 2021;21(7):573-588. doi: 10.2174/1566524020999201203212824.
 155. Bastaki S, Aravindhana S, Ahmadpour Saheb N, Afsari Kashani M, Evgenievich Dorofeev A, Karoon Kiani F, Jahandideh H, Beigi Dargani F, Aksoun M, Nikkhoo A, Masjedi A, Mahmoodpoor A, Ahmadi M, Dolati S, Namvar Aghdash S, **Jadidi-Niaragh**

- F***. Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice. *Life Sci.* 2021 Feb 1;266:118847. doi: 10.1016/j.lfs.2020.118847.
156. Local Burden of Disease Vaccine Coverage Collaborators. Mapping routine measles vaccination in low- and middle-income countries. *Nature.* 2021 Jan;589(7842):415-419. doi: 10.1038/s41586-020-03043-4.
 157. Khelghati N, Soleimanpour Mokhtarvand J, Mir M, Alemi F, Asemi Z, Sadeghpour A, Maleki M, Samadi Kafil H, **Jadidi-Niaragh F**, Majidinia M, Yousefi B. The importance of co-delivery of nanoparticle-siRNA and anticancer agents in cancer therapy. *Chem Biol Drug Des.* 2021 Apr;97(4):997-1015. doi: 10.1111/cbdd.13824.
 158. Karpishev V, Mousavi SM, Naghavi Sheykholeslami P, Fathi M, Mohammadpour Saray M, Aghebat-Maleki L, Jafari R, Majidi Zolbanin N, **Jadidi-Niaragh F***. The role of regulatory T cells in the pathogenesis and treatment of prostate cancer. *Life Sci.* 2021 Nov 1;284:119132. doi: 10.1016/j.lfs.2021.119132.
 159. Ramezani F, Babaie F, Aslani S, Hemmatzadeh M, Mohammadi FS, Gowhari-Shabgah A, **Jadidi-Niaragh F**, Ezzatifar F, Mohammadi H. The Role of the IL-33/ST2 Immune Pathway in Autoimmunity: New Insights and Perspectives. *Immunol Invest.* 2021 Feb 1:1-27. doi: 10.1080/08820139.2021.1878212.
 160. Ebrazeh M, Ezzatifar F, Torkamandi S, Mohammadi FS, Salimifard S, Gowhari Shabgah A, Hemmatzadeh M, Aslani S, Babaie F, **Jadidi-Niaragh F**, Gholizadeh Navashenag J, Mohammadi H. Association of the genetic variants in the endoplasmic reticulum aminopeptidase 2 gene with ankylosing spondylitis susceptibility. *Int J Rheum Dis.* 2021 Apr;24(4):567-581. doi: 10.1111/1756-185X.14079.
 161. Dolati S, Shakouri SK, Dolatkhan N, Yousefi M, **Jadidi-Niaragh F**, Sanaie S. The role of exosomal non-coding RNAs in aging-related diseases. *Biofactors.* 2021 May;47(3):292-310. doi: 10.1002/biof.1715.
 162. Budi HS, Izadi S, Timoshin A, Asl SH, Beyzai B, Ghaderpour A, Alian F, Eshaghi FS, Mousavi SM, Rafiee B, Nikkhoo A, Ahmadi A, Hassannia H, Ahmadi M, Sojoodi M, **Jadidi-Niaragh F***. Blockade of HIF-1 α and STAT3 by hyaluronate-conjugated TAT-chitosan-SPION nanoparticles loaded with siRNA molecules prevents tumor growth. *Nanomedicine.* 2021 Jun;34:102373. doi: 10.1016/j.nano.2021.102373.
 163. Lotfinejad P, Kazemi T, Safaei S, Amini M, Roshani Asl E, Baghbani E, Sandoghchian Shotorbani S, **Jadidi Niaragh F**, Derakhshani A, Abdoli Shadbad M, Silvestris N, Baradaran B. PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines. *Biomed Pharmacother.* 2021 Jun;138:111436. doi: 10.1016/j.biopha.2021.111436.
 164. Fathi M, Pustokhina I, Kuznetsov SV, Khayrullin M, Hojjat-Farsangi M, Karpishev V, Jalili A, **Jadidi-Niaragh F***. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer. *IUBMB Life.* 2021 May;73(5):726-738. doi: 10.1002/iub.2461.
 165. Tahmasebi S, Qasim MT, Krivenkova MV, Zekiy AO, Thangavelu L, Aravindhan S, Izadi M, **Jadidi-Niaragh F**, Ghaebi M, Aslani S, Aghebat-Maleki L, Ahmadi M, Roshangar L. The effects of oxygen-ozone therapy on regulatory T-cell responses in multiple sclerosis patients. *Cell Biol Int.* 2021 Jul;45(7):1498-1509. doi: 10.1002/cbin.11589.

166. Joshi N, Hajizadeh F, Ansari Dezfouli E, Zekiy AO, Nabi Afjadi M, Mousavi SM, Hojjat-Farsangi M, Karpishev V, Mahmoodpoor A, Hassannia H, Dolati S, Mohammadi H, Yousefi M, **Jadidi-Niaragh F***. Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression. *Life Sci.* 2021 Jun 15;275:119369. doi: 10.1016/j.lfs.2021.119369
167. Allahyari SE, Hajizadeh F, Zekiy AO, Mansouri N, Gilan PS, Mousavi SM, Masjedi A, Hassannia H, Ahmadi M, Mohammadi H, Yousefi M, Izadi S, Zolbanin NM, Jafari R, **Jadidi-Niaragh F***. Simultaneous inhibition of CD73 and IL-6 molecules by siRNA-loaded nanoparticles prevents the growth and spread of cancer. *Nanomedicine.* 2021 Jun;34:102384. doi: 10.1016/j.nano.2021.102384.
168. Hosseini A, Gharibi T, Mohammadzadeh A, Ebrahimi-Kalan A, **Jadidi-Niaragh F**, Babaloo Z, Shanebandi D, Baghbani E, Baradaran B. Ruxolitinib attenuates experimental autoimmune encephalomyelitis (EAE) development as animal models of multiple sclerosis (MS). *Life Sci.* 2021 Jul 1;276:119395. doi: 10.1016/j.lfs.2021.119395
169. Tahmasebi S, Saeed BQ, Temirgalieva E, Yumashev AV, El-Esawi MA, Navashenaq JG, Valizadeh H, Sadeghi A, Aslani S, Yousefi M, **Jadidi-Niaragh F**, Adigozalou J, Ahmadi M, Roshangar L. Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2. *Life Sci.* 2021 Jul 1;276:119437. doi: 10.1016/j.lfs.2021.119437
170. Zolfaghari MA, Motavalli R, Soltani-Zangbar MS, Parhizkar F, Danaii S, Aghebati-Maleki L, Noori M, Dolati S, Ahmadi M, Samadi Kafil H, **Jadidi-Niaragh F**, Ahmadian Heris J, Mahmoodpoor A, Hejazi MS, Yousefi M. A new approach to the preeclampsia puzzle; MicroRNA-326 in CD4+ lymphocytes might be as a potential suspect. *J Reprod Immunol.* 2021 Jun;145:103317. doi: 10.1016/j.jri.2021.103317.
171. Kamrani A, Soltani-Zangbar MS, Shiri S, Yousefzadeh Y, Pourakbari R, Aghebati-Maleki L, Mehdizadeh A, Danaii S, **Jadidi-Niaragh F**, Yousefi B, Kafil HS, Hojjat-Farsangi M, Motavalli R, Zolfaghari M, Haji-Fatahaliha M, Mahmoodpoor A, Ahmadian Heris J, Emdadi A, Yousefi M. TIGIT and CD155 as Immune-Modulator Receptor and Ligand on CD4+ T cells in Preeclampsia Patients. *Immunol Invest.* 2021 Apr 15:1-16. doi: 10.1080/08820139.2021.1904976.
172. Soltani-Zangbar MS, Aghebati-Maleki L, Hajivalili M, Haji-Fatahaliha M, Motavalli R, Mahmoodpoor A, Kafil HS, Farhang S, Pourakbari R, **Jadidi-Niaragh F**, Roshangar L, Heris JA, Kamrani A, Siahmansouri H, Hosseini M, Miahpour A, Shareghi-Oskoue O, Parhizkar F, Yousefi M. Application of newly developed SARS-CoV2 serology test along with real-time PCR for early detection in health care workers and on-time plasma donation. *Gene Rep.* 2021 Jun;23:101140. doi: 10.1016/j.genrep.2021.101140.
173. Mahmoud Salehi Khesht A, Karpishev V, Qubais Saeed B, Olegovna Zekiy A, Yapanto LM, Nabi Afjadi M, Aksoun M, Nasr Esfahani M, Aghakhani F, Movahed M, Joshi N, Abbaszadeh-Goudarzi K, Hallaj S, Ahmadi M, Dolati S, Mahmoodpoor A, Hashemi V, **Jadidi-Niaragh F***. Different T cell related immunological profiles in COVID-19 patients compared to healthy controls. *Int Immunopharmacol.* 2021 Aug;97:107828. doi: 10.1016/j.intimp.2021.107828.
174. Widjaja G, Turki Jalil A, Sulaiman Rahman H, Abdelbasset WK, Bokov DO, Suksatan W, Ghaebi M, Marofi F, Gholizadeh Navashenaq J, **Jadidi-Niaragh F**, Ahmadi M. Humoral immune mechanisms involved in protective and pathological immunity

- during COVID-19. *Hum Immunol.* 2021 Oct;82(10):733-745. doi: 10.1016/j.humimm.2021.06.011.
175. Salehi Khesht AM, Karpisheh V, Sahami Gilan P, Melnikova LA, Olegovna Zekiy A, Mohammadi M, Hojjat-Farsangi M, Majidi Zolbanin N, Mahmoodpoor A, Hassannia H, Aghebati-Maleki L, Jafari R, **Jadidi-Niaragh F***. Blockade of CD73 using siRNA loaded chitosan lactate nanoparticles functionalized with TAT-hyaluronate enhances doxorubicin mediated cytotoxicity in cancer cells both in vitro and in vivo. *Int J Biol Macromol.* 2021 Sep 1;186:849-863. doi: 10.1016/j.ijbiomac.2021.07.034.
 176. Hallaj S, Mirza-Aghazadeh-Attari M, Arasteh A, Ghorbani A, Lee D, **Jadidi-Niaragh F***. Adenosine: The common target between cancer immunotherapy and glaucoma in the eye. *Life Sci.* 2021 Oct 1;282:119796. doi: 10.1016/j.lfs.2021.119796
 177. Vakili-Samiani S, Turki Jalil A, Abdelbasset WK, Yumashev AV, Karpisheh V, Jalali P, Adibfar S, Ahmadi M, Hosseinpour Feizi AA, **Jadidi-Niaragh F***. Targeting Wee1 kinase as a therapeutic approach in Hematological Malignancies. *DNA Repair (Amst).* 2021 Nov;107:103203. doi: 10.1016/j.dnarep.2021.103203
 178. Shabgah AG, Suksatan W, Achmad MH, Bokov DO, Abdelbasset WK, Ezzatifar F, Hemmati S, Mohammadi H, Soleimani D, **Jadidi-Niaragh F**, Ahmadi M, Navashenaq JG. Arctigenin, an anti-tumor agent; a cutting-edge topic and up-to-the-minute approach in cancer treatment. *Eur J Pharmacol.* 2021 Oct 15;909:174419. doi: 10.1016/j.ejphar.2021.174419.
 179. Mohammadhosayni M, Sadat Mohammadi F, Ezzatifar F, Mahdavi Gorabi A, Khosrojerdi A, Aslani S, Hemmatzadeh M, Yazdani S, Arabi M, Marofi F, **Jadidi-Niaragh F**, Shomali N, Mohammadi H. Matrix metalloproteinases are involved in the development of neurological complications in patients with Coronavirus disease 2019. *Int Immunopharmacol.* 2021 Nov;100:108076. doi: 10.1016/j.intimp.2021.108076.
 180. Hosseinzadeh R, Feizisani F, Shomali N, Abdelbasset WK, Hemmatzadeh M, Gholizadeh Navashenaq J, **Jadidi-Niaragh F**, Bokov DO, Janebifam M, Mohammadi H. PD-1/PD-L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity. *IUBMB Life.* 2021 Nov;73(11):1293-1306. doi: 10.1002/iub.2558.
 181. Kinyoki D, Osgood-Zimmerman AE, Bhattacharjee NV; Local Burden of Disease Anaemia Collaborators, Kassebaum NJ, Hay SI. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018. *Nat Med.* 2021 Oct;27(10):1761-1782. doi: 10.1038/s41591-021-01498-0.
 182. Adibfar S, Elveny M, Kashikova HS, Mikhailova MV, Farhangnia P, Vakili-Samiani S, Tarokhian H, **Jadidi-Niaragh F***. The molecular mechanisms and therapeutic potential of EZH2 in breast cancer. *Life Sci.* 2021 Dec 1;286:120047. doi: 10.1016/j.lfs.2021.120047.
 183. Fathi M, Bahmanpour S, Barshidi A, Rasouli H, Karoon Kiani F, Mahmoud Salehi Khesht A, Izadi S, Rashidi B, Kermanpour S, Mokhtarian R, Karpisheh V, Hassannia H, Mohammadi H, Jalili A, **Jadidi-Niaragh F***. Simultaneous blockade of TIGIT and HIF-1 α induces synergistic anti-tumor effect and decreases the growth and development of cancer cells. *Int Immunopharmacol.* 2021 Dec;101(Pt A):108288. doi: 10.1016/j.intimp.2021.108288.
 184. GBD 2019 Adolescent Young Adult Cancer Collaborators. The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden

- of Disease Study 2019. *Lancet Oncol.* 2022 Jan;23(1):27-52. doi: 10.1016/S1470-2045(21)00581-7.
185. Gowhari Shabgah A, Jaber Al-Obaidi ZM, Rahman HS, Abdelbasset WK, Suksatan W, Bokov DO, Thangavelu L, Turki Jalil A, **Jadidi-Niaragh F**, Mohammadi H, Mashayekhi K, Gholizadeh Navashenaq Does CCL19 act as a double-edged sword in cancer development? *J. Clin Exp Immunol.* 2021 Dec 28:uxab039. doi: 10.1093/cei/uxab039.
 186. Karpisheh V, Ahmadi M, Abbaszadeh-Goudarzi K, Mohammadpour Saray M, Barshidi A, Mohammadi H, Yousefi M, **Jadidi-Niaragh F***. The role of Th17 cells in the pathogenesis and treatment of breast cancer. *Cancer Cell Int.* 2022 Mar 5;22(1):108. doi: 10.1186/s12935-022-02528-8.
 187. Hojjatipour T, Aslani S, Salimifard S, Mikaeili H, Hemmatzadeh M, Gholizadeh Navashenaq J, Ahangar Parvin E, **Jadidi-Niaragh F***, Mohammadi H. NK cells - Dr. Jekyll and Mr. Hyde in autoimmune rheumatic diseases. *Int Immunopharmacol.* 2022 Mar 5;107:108682. doi: 10.1016/j.intimp.2022.108682.
 188. Vesaghhamedani S, Ebrahimzadeh F, Najafi E, Shabgah OG, Askari E, Shabgah AG, Mohammadi H, **Jadidi-Niaragh F**, Navashenaq JG. Xanthohumol: An underestimated, while potent and promising chemotherapeutic agent in cancer treatment. *Prog Biophys Mol Biol.* 2022 Aug;172:3-14. doi: 10.1016/j.pbiomolbio.2022.04.002.
 189. The Role of Atypical Chemokine Receptor D6 (ACKR2) in Physiological and Pathological Conditions; Friend, Foe, or Both? Gowhari Shabgah A, **Jadidi-Niaragh F**, Mohammadi H, Ebrahimzadeh F, Oveisee M, Jahanara A, Gholizadeh Navashenaq J. *Front Immunol.* 2022 May 23;13:861931. doi: 10.3389/fimmu.2022.861931. eCollection 2022.
 190. Abbaszadeh H, Ghorbani F, Abbaspour-Aghdam S, Kamrani A, Valizadeh H, Nadiri M, Sadeghi A, Shamsasenjan K, **Jadidi-Niaragh F**, Roshangar L, Ahmadi M. Chronic obstructive pulmonary disease and asthma: mesenchymal stem cells and their extracellular vesicles as potential therapeutic tools. *Stem Cell Res Ther.* 2022 Jun 20;13(1):262. doi: 10.1186/s13287-022-02938-5.
 191. GBD 2019 Hepatitis B Collaborators. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Gastroenterol Hepatol.* 2022 Sep;7(9):796-829. doi: 10.1016/S2468-1253(22)00124-8.
 192. Gowhari Shabgah A, **Jadidi-Niaragh F**, Ebrahimzadeh F, Mohammadi H, Askari E, Pahlavani N, Malekahmadi M, Ebrahimi Nik M, Gholizadeh Navashenaq J. A comprehensive review of chemokine CXCL17 (XCL1) in cancer, infection, and inflammation. *Cell Biol Int.* 2022 Oct;46(10):1557-1570. doi: 10.1002/cbin.11846.
 193. Abolhasani S, Hejazian SS, Karpisheh V, Khodakarami A, Mohammadi H, Gholizadeh Navashenaq J, Hojjat-Farsangi M, **Jadidi-Niaragh F**. The role of SF3B1 and NOTCH1 in the pathogenesis of leukemia. *IUBMB Life.* 2023 Mar;75(3):257-278. doi: 10.1002/iub.2660.
 194. Madadi S, Mohammadinejad S, Alizadegan A, Hojjat-Farsangi M, Dolati S, Samadi Kafil H, **Jadidi-Niaragh F**, Soltani-Zangbar MS, Motavalli R, Etemadi J, Eghbal-Fard S, Aghebati-Maleki L, Danaii S, Taghavi S, Yousefi M. Expression level of immune checkpoint inhibitory factors in preeclampsia. *Hum Immunol.* 2022 Aug-Sep;83(8-9):628-636. doi: 10.1016/j.humimm.2022.07.004.

195. Khodakarami A, Adibfar S, Karpisheh V, Abolhasani S, Jalali P, Mohammadi H, Gholizadeh Navashenaq J, Hojjat-Farsangi M, Jadidi-Niaragh F. The molecular biology and therapeutic potential of Nrf2 in leukemia. *Cancer Cell Int.* 2022 Jul 29;22(1):241. doi: 10.1186/s12935-022-02660-5.
196. Hemmatzadeh M, Ahangar Parvin E, Mohammadi H, Azizi G, Shomali N, **Jadidi-Niaragh F**. The role of immune regulatory molecules in rheumatoid arthritis: Implication for etiopathogenesis and prospective for treatment. *J Cell Physiol.* 2022 Sep;237(9):3541-3553. doi: 10.1002/jcp.30855.
197. Yousefzadeh Y, Soltani-Zangbar MS, Kalafi L, Tarbiat A, Shahmohammadi Farid S, Aghebati-Maleki L, Parhizkar F, Danaii S, Taghavi S, **Jadidi-Niaragh F**, Samadi Kafil H, Mahmoodpoor A, Ahmadian Heris J, Hojjat-Farsangi M, Yousefi M. Evaluation of CD39, CD73, HIF-1 α , and their related miRNAs expression in decidua of preeclampsia cases compared to healthy pregnant women. *Mol Biol Rep.* 2022 Nov;49(11):10183-10193. doi: 10.1007/s11033-022-07887-z.
198. Sadeghi M, Sepasi K, Alamdari AH, Akbari AAM, Feizi AAH, Farid SS, **Jadidi-Niaragh F**. Bcl-2 Inhibition Induces a Synergistic Effect in Combination with Doxorubicin in Chronic Lymphocytic Leukemia. *ImmunoAnalysis*, 2022; 2 (1), 14-14.
199. Sadeghi M, Bostanabad MY, Abedi O, Feizi AAH, Akbari AAM, **Jadidi-Niaragh F**. Blockade of CD73 Increases the Cytotoxic Effects of Fludarabine in Chronic Lymphocytic Leukemia. *ImmunoAnalysis*, 2022; 2 (1), 11.
200. Sadeghi M, Hajibaba HH, Valizadeh Y, Akbari AAM, Feizi AAH, Movasaghpour Akbari AA, **Jadidi-Niaragh F**. Combinational Therapy of Acute Lymphoblastic Leukemia with Cyclophosphamide and BV6 Synergistically Induces Apoptosis in Leukemic Cells. *ImmunoAnalysis*, 2022; 2 (1), 9-9.
201. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. GBD 2019 Hepatitis B Collaborators *Lancet Gastroenterol Hepatol.* 2022 Sep;7(9):796-829. doi: 10.1016/S2468-1253(22)00124-8. Epub 2022 Jun 21.
202. Abbaspour-Aghdam S, Hazrati A, Abdolmohammadi-Vahid S, Tahmasebi S, Mohseni J, Valizadeh H, Nadiri M, Mikaeili H, Sadeghi A, Yousefi M, Roshangar L, Nikzad B, **Jadidi-Niaragh F**, Kafil HS, Malekpour K, Ahmadi M. Immunomodulatory role of Nanocurcumin in COVID-19 patients with dropped natural killer cells frequency and function. *Eur J Pharmacol.* 2022 Oct 15;933:175267. doi: 10.1016/j.ejphar.2022.175267.
203. Pourakbari R, Parhizkar F, Soltani-Zangbar MS, Samadi P, Zamani M, Aghebati-Maleki L, Motavalli R, Mahmoodpoor A, **Jadidi-Niaragh F**, Yousefi B, Kafil HS, Hojjat-Farsangi M, Danaii S, Yousefi M. Preeclampsia-Derived Exosomes Imbalance the Activity of Th17 and Treg in PBMCs from Healthy Pregnant Women. *Reprod Sci.* 2022 Sep 26. doi: 10.1007/s43032-022-01059-x.
204. Adibfar S, Masjedi A, Nazer A, Rashidi B, Karpisheh V, Izadi S, Hassannia H, Gholizadeh Navashenaq J, Mohammadi H, Hojjat-Farsangi M, Tarokhian H, **Jadidi-Niaragh F**. Combined inhibition of EZH2 and CD73 molecules by folic acid-conjugated SPION-TMC nanocarriers loaded with siRNA molecules prevents TNBC progression and restores anti-tumor responses. *Life Sci.* 2022 Nov 15;309:121008. doi: 10.1016/j.lfs.2022.121008.

205. Feizi H, Rezaee MA, Ghotaslou R, Sadrkabir M, **Jadidi-Niaragh F**, Gholizadeh P, Taghizadeh S, Ghanbarov K, Yousefi M, Kafil HS. Gut microbiota and colorectal cancer risk factors. *Curr Pharm Biotechnol.* 2022 Oct 5. doi: 10.2174/1389201023666221005103340.
206. Association of the matrix metalloproteinases (MMPs) family gene polymorphisms and the risk of coronavirus disease 2019 (COVID-19); implications of contribution for development of neurological symptoms in the COVID-19 patients.
207. Ramezani S, Ezzatifar F, Hojjatipour T, Hemmatzadeh M, Shabgah AG, Navashenaq JG, Aslani S, Shomali N, Arabi M, Babaie F, **Jadidi-Niaragh F**, Hosseinzadeh R, Feizisani F, Khodayar S, Safari R, Mohammadi H. *Mol Biol Rep.* 2023 Jan;50(1):173-183. doi: 10.1007/s11033-022-07907-y.
208. Fathi M, Razavi SM, Sojoodi M, Ahmadi A, Ebrahimi F, Namdar A, Hojjat-Farsangi M, Gholamin S, **Jadidi-Niaragh F**. Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventions. *Expert Opin Ther Targets.* 2022 Nov;26(11):949-961. doi: 10.1080/14728222.2022.2160703.
209. Hemmatzadeh M, Ahangar Parvin E, Ghanavatinejad A, Rostami N, Hajaliloo M, Shomali N, Mohammadi H, **Jadidi-Niaragh F**. MicroRNAs Targeting Programmed Cell Death Protein 1 (PD-1) Promote Natural Killer Cell Exhaustion in Rheumatoid Arthritis. *Iran J Allergy Asthma Immunol.* 2022 Dec 24;21(6):646-656. doi: 10.18502/ijaai.v21i6.11524.
210. Sadeghi M, Khodakarami A, Ahmadi A, Fathi M, Gholizadeh Navashenaq J, Mohammadi H, Yousefi M, Hojjat-Farsangi M, Movasaghpour Akbari AA, **Jadidi-Niaragh F**. The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies. *Expert Opin Ther Targets.* 2022 Dec;26(12):1057-1071. doi: 10.1080/14728222.2022.2170781.
211. Ehteshaminia Y, Jalali SF, **Jadidi-Niaragh F**, Enderami SE, Pagheh AS, Akbari E, Kenari SA, Hassannia H. Enhancement of immunogenicity and neutralizing responses against SARS-CoV-2 spike protein using the Fc fusion fragment. *Life Sci.* 2023 Feb 24;320:121525. doi: 10.1016/j.lfs.2023.121525.
212. Sadeghi M, Fathi M, Gholizadeh Navashenaq J, Mohammadi H, Yousefi M, Hojjat-Farsangi M, Namdar A, Movasaghpour Akbari AA, **Jadidi-Niaragh F**. The prognostic and therapeutic potential of HO-1 in leukemia and MDS. *Cell Commun Signal.* 2023 Mar 13;21(1):57. doi: 10.1186/s12964-023-01074-8.
213. Parhizkar F, Yousefi M, Soltani-Zangbar MS, Parhizkar Z, Aghebati-Maleki L, Abbaspour-Ravasjani S, Motavalli R, Alizadegan A, Mojahedi M, Baharaghdam S, Kamrani A, Danaii S, Talebi M, **Jadidi-Niaragh F**, Hamishehkar H, Kafil HS, Mahmoodpoor A, Heris JA. Sirolimus- and cyclosporine-loaded nanostructured lipid carriers: Development, characterization, and in vitro evaluation in T-cell profiles of patients with a history of recurrent pregnancy loss. *Reprod Med Biol.* 2023 Mar 20;22(1):e12509. doi: 10.1002/rmb2.12509. eCollection 2023 Jan-Dec.
214. Abolhasani S, Javadi S, Hassannia H, Ghalamfarsa G, Hojjat-Farsangi M, **Jadidi-Niaragh F**, IGF1R and HIF-1 α Gene Silencing Inhibits Cancer Cell Growth, *International Journal of Drug Research in Clinics*, 2023; 1 (1), e17-e17.
215. Sadeghi M, Aghebati-Maleki L, Abbaszadeh S, Rasoulzadeh S, Feizi AAH, Movasaghpour Akbari AA, **Jadidi-Niaragh F**. Silencing of mTOR Facilitates the

Cyclophosphamide-Mediated Cytotoxicity in Acute Lymphoblastic Leukemia
ImmunoAnalysis, 20233; (1), 1-1

216. Izadi S, Hojjat-Farsangi M, Karpisheh V, **Jadidi-Niaragh F**. Pan Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer. *International Journal of Drug Research in Clinics* 2023; 1 (1), e2-e2.
217. **Jadidi-Niaragh F**, Tumor Microenvironment Management: Can It Be the Solution to Cancer Treatment?, *International Journal of Aging*, 2023, 1, e1910.34172/ija.2023.e19.
218. Jalali SF, **Jadidi-Niaragh F**, Enderami E, Pagheh AS, Akbari E, Abedian Kenari S, Hassannia H. Characterization of Fixatives and their Application in Histopathology, *Biomedical Journal of Scientific & Technical Research* 2023; 47 (5), 38945-38953.
219. Khodakarami A, Darvishi S, Hassannia H, Sadeghi M, Esmaeeli S, Hashemi V, Hojjat-Farsangi M, Jadidi-Niaragh F. Blockade of CD155 and interleukin-6 suppresses breast cancer cell growth, *International Journal of Drug Research in Clinics*. 2023.
220. Vesaghhamedani S, Mazloumi Kiapey SS, Gowhari Shabgah A, Amiresmaili S, Jahanara A, Oveisee M, Shekarchi A, Gheibihayat SM, **Jadidi-Niaragh F**, Gholizadeh Navashenaq. From traditional medicine to modern oncology: Scutellarin, a promising natural compound in cancer treatment. *J. Prog Biophys Mol Biol*. 2023 Jul-Aug;180-181:19-27.
221. Kalaei Z, Manafi-Farid R, Rashidi B, Kiani FK, Zarei A, Fathi M, **Jadidi-Niaragh F**. The Prognostic and therapeutic value and clinical implications of fibroblast activation protein- α as a novel biomarker in colorectal cancer. *Cell Commun Signal*. 2023 Jun 14;21(1):139.
222. Motallebnezhad M, Hazrati A, Esmaeili Gouvarchin Ghaleh H, Jonaiddi-Jafari N, Abbaspour-Aghdam S, Malekpour K, Yousefi M, Samadi Kafil H, **Jadidi-Niaragh F**, Roshangar L, Valizadeh H, Izadi M, Ahmadi M. Exosomes from Adipose Tissue-derived Mesenchymal Stem Cells Induce Regulatory T Cells in COVID-19 Patients. *Iran J Allergy Asthma Immunol*. 2023 Jun 16;22(3):233-244. doi: 10.18502/ijaai.v22i3.13051.
223. Akbari B, Soltantoyeh T, Shahosseini Z, **Jadidi-Niaragh F**, Hadjati J, Brown CE, Mirzaei HR. PGE2-EP2/EP4 signaling elicits mesoCAR T cell immunosuppression in pancreatic cancer. *Front Immunol*. 2023 Jun 30;14:1209572. doi: 10.3389/fimmu.2023.1209572. eCollection 2023.
224. Khodakarami A, Kashani MA, Nazer A, Kheshti AM, Rashidi B, Karpisheh V, Masjedi A, Abolhasani S, Izadi S, Bagherifar R, Hejazian SS, Mohammadi H, Movassaghpour A, Feizi AAH, Hojjat-Farsangi M, **Jadidi-Niaragh F**. Targeted Silencing of NRF2 by rituximab-conjugated nanoparticles increases the sensitivity of chronic lymphoblastic leukemia cells to Cyclophosphamide. *Cell Commun Signal*. 2023 Aug 1;21(1):188. doi: 10.1186/s12964-023-01213-1.
225. Neonate, Infant, and Child Mortality in North Africa and Middle East by Cause: An Analysis for the Global Burden of Disease Study 2019.
Sapanlou SG, Rezaei Aliabadi H, Malekzadeh R, Naghavi M; GBD Child Mortality in Middle East Collaborators. *Arch Iran Med*. 2022 Dec 1;25(12):767-778. doi: 10.34172/aim.2022.122.
226. Ahmadvpour E, Spotin A, Moghimi A, Shahrivar F, **Jadidi-Niaragh F**, Hajizadeh F, Mehrani S, Mazhab-Jafari K. Tumor suppressor p73 induces apoptosis of murine peritoneal cell after exposure to hydatid cyst antigens; a possibly survival mechanism of

- cystic echinococcosis in vivo mice model. *PLoS One*. 2023 Oct 5;18(10):e0292434. doi: 10.1371/journal.pone.0292434. eCollection 2023.
227. Mahmoudi G, Ehteshaminia Y, Kokhaei P, Jalali SF, **Jadidi-Niaragh F**, Pagheh AS, Enderami SE, Kenari SA, Hassannia H. Enhancement of targeted therapy in combination with metformin on human breast cancer cell lines. *Cell Commun Signal*. 2024 Jan 2;22(1):10. doi: 10.1186/s12964-023-01446-0.
 228. Ranjbaran H, Ehteshaminia Y, Nadernezhad M, Jalali SF, Jadidi-Niaragh F, Pagheh AS, Enderami SE, Kenari SA, Hassannia H. Comparison of neutralization potency across passive immunotherapy approaches as potential treatments for emerging infectious diseases. *Heliyon*. 2023 Dec 16;10(1):e23478. doi: 10.1016/j.heliyon.2023.e23478. eCollection 2024 Jan 15.
 229. Barshidi A, Ardeshiri K, Ebrahimi F, Alian F, Shekarchi AA, Hojjat-Farsangi M, Jadidi-Niaragh F. The role of exhausted natural killer cells in the immunopathogenesis and treatment of leukemia. *Cell Commun Signal*. 2024 Jan 22;22(1):59. doi: 10.1186/s12964-023-01428-2.
 230. Temporal patterns of cancer burden in Asia, 1990-2019: a systematic examination for the Global Burden of Disease 2019 study. GBD 2019 Asia and All Cancers Collaborators. *Lancet Reg Health Southeast Asia*. 2024 Jan 2;21:100333. doi: 10.1016/j.lansea.2023.100333.
 231. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. GBD 2021 Demographics Collaborators. *Lancet*. 2024 May 18;403(10440):1989-2056. doi: 10.1016/S0140-6736(24)00476-8.
 232. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. GBD 2021 Nervous System Disorders Collaborators. *Lancet Neurol*. 2024 Apr;23(4):344-381. doi: 10.1016/S1474-4422(24)00038-3.
 233. Global fertility in 204 countries and territories, 1950-2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. GBD 2021 Fertility and Forecasting Collaborators. *Lancet*. 2024 May 18;403(10440):2057-2099. doi: 10.1016/S0140-6736(24)00550-6.
 234. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. GBD 2021 Causes of Death Collaborators. *Lancet*. 2024 May 18;403(10440):2100-2132. doi: 10.1016/S0140-6736(24)00367-2.
 235. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. GBD 2021 Diseases and Injuries Collaborators. *Lancet*. 2024 May 18;403(10440):2133-2161. doi: 10.1016/S0140-6736(24)00757-8.
 236. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. GBD 2021 Risk Factors Collaborators. *Lancet*. 2024 May 18;403(10440):2162-2203. doi: 10.1016/S0140-6736(24)00933-4.

237. Sadeghi M, Moslehi A, Kheiry H, Kiani FK, Zarei A, Khodakarami A, Karpishev V, Masjedi A, Rahnama B, Hojjat-Farsangi M, Raeisi M, Yousefi M, Movasaghpour Akbari AA, **Jadidi-Niaragh F**. The sensitivity of acute myeloid leukemia cells to cytarabine is increased by suppressing the expression of Heme oxygenase-1 and hypoxia-inducible factor 1-alpha. *Cancer Cell Int*. 2024 Jun 25;24(1):217. doi: 10.1186/s12935-024-03393-3.
238. Datshi M, Habibi MA, Nejati N, Robat-Jazi B, Ahmadpour M, Dokhani N, Nejad AR, Karami S, Alinejad E, Malekijoo AH, Ghasemzadeh A, **Jadidi-Niaragh F**. Clinical Efficacy and Safety of CD7-Targeted CAR T Cell Therapy for T-cell Malignancies: A Systematic Review and Meta-analysis. *Anticancer Agents Med Chem*. 2024 Aug 26. doi: 10.2174/0118715206321313240820101412.
239. Bakhshivand M, Masoumi J, Ghorbaninezhad F, Aghebati-Maleki L, Shanebandi D, Sandoghchian Shotorbani S, **Jadidi-Niaragh F**, Baghbanzadeh A, Hemmat N, Baghbani E, Ghaffari A, Baradaran B. Boosting Immunotherapy Efficacy: Empowering the Potency of Dendritic Cells Loaded with Breast Cancer Lysates through CTLA-4 Suppression, *Heliyon*, 2024.

EDITORIAL EXPERIENCE

➤ Review Editor in section Microbial Immunology for *Frontiers in Immunology* (<https://loop.frontiersin.org/people/83674/editorial>)

➤ Associate Editor for *International Journal of Aging* (<http://www.ijage.com/EditorialBoard>)

➤ Reviewed manuscripts for: (237 Verified peer reviews at <https://www.webofscience.com/wos/author/record/93667>)

- Nature Reviews Clinical Oncology
- Frontiers Journals
- International journal of biological macromolecules
- Nanomedicine
- Biomaterials
- Acta Biomaterialia
- Heliyon
- Expert opinion on therapeutic targets

Book Chapters

1. Jadidi-Niaragh F, Mirshafiey A, Regulatory T Cells and Multiple Sclerosis, LAP Lambert Academic Publishing GmbH & Co. Published: May 2012, ISBN-13: 9783659120343. ISBN-10: 3659120340
2. Myeloid-Derived Suppressor Cells and Macrophage Polarization in Cancer Immunotherapy
MS Hosseini, MA Akbarzadeh, F Jadidi-Niaragh
Critical Developments in Cancer Immunotherapy, 157-204